Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Unfair Advantage’s Substack by AK. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $38.52 as of April 23rd. NVO’s trailing and forward P/E were 10.65 and 11.38 respectively according to Yahoo Finance.
Photo by Myriam Zilles on Unsplash
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. NVO is regaining momentum in the obesity drug market, with its stock rising 18% since prior analysis while still trading at a significant discount to Eli Lilly despite improving fundamentals.
The company has recently gained a strategic edge through strong early demand for its oral semaglutide and a delay in FDA approval of Eli Lilly’s competing pill, giving Novo a crucial head start in a highly competitive market.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Management has acted decisively, appointing a new CEO and board, implementing pricing cuts, and restructuring operations, including a 9,000-employee reduction, signaling a more disciplined and aggressive approach after prior missteps that led to market share losses. While clinical comparisons show Eli Lilly’s tirzepatide has superior weight-loss efficacy at peak doses, real-world data suggests most patients do not reach those levels, narrowing the practical gap between the two drugs.
Novo’s semaglutide also demonstrates strong cardiovascular benefits, positioning it for expansion into adjacent therapeutic areas. Pricing strategy has emerged as a key differentiator, with Novo offering uniform and significantly lower pricing across doses, improving affordability and competitiveness against both Eli Lilly and compounded alternatives.
Distribution has also improved materially, highlighted by CVS Caremark favoring Wegovy over Eli Lilly’s Zepbound, which should drive volume growth over time. With a temporary monopoly in GLP-1 pills, favorable pricing, and expanding access channels, Novo Nordisk is well positioned to recapture lost share and capitalize on a large, growing obesity market, supporting a bullish outlook.
Previously, we covered a bullish thesis on Novo Nordisk A/S (NVO) by Kontra Investments in May 2025, which highlighted the company’s strong financial performance, GLP-1 dominance, and expanding pipeline supporting long-term growth. NVO’s stock price has depreciated by approximately 43.13% since our coverage. AK shares a similar view but emphasizes on Novo’s competitive repositioning through oral semaglutide, pricing, and distribution advantages.
Novo Nordisk A/S is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 55 hedge fund portfolios held NVO at the end of the fourth quarter which was 50 in the previous quarter. While we acknowledge the risk and potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVO and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
